The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_005633.3(SOS1):c.1656G>C (p.Arg552Ser)

CA256580

12872 (ClinVar)

Gene: SOS1
Condition: RASopathy
Inheritance Mode: Autosomal dominant inheritance
UUID: 7b69757f-5512-4640-93f6-c926e38cf7f9

HGVS expressions

NM_005633.3:c.1656G>C
NM_005633.3(SOS1):c.1656G>C (p.Arg552Ser)
NC_000002.12:g.39022772C>G
CM000664.2:g.39022772C>G
NC_000002.11:g.39249913C>G
CM000664.1:g.39249913C>G
NC_000002.10:g.39103417C>G
NG_007530.1:g.102692G>C
ENST00000395038.6:c.1656G>C
ENST00000402219.6:c.1656G>C
ENST00000426016.5:c.1656G>C

Pathogenic

Met criteria codes 7
PS2_Very Strong PS3 PS4 PP2 PP3 PM2 PM1_Strong
Not Met criteria codes 16
BA1 BS1 BS3 BS4 BS2 BP5 BP7 BP2 BP1 BP4 BP3 PS1 PP1 PM4 PM5 PM6

Evidence Links 16

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
RASopathy VCEP
The c.1656G>C (p.Arg552Ser) variant in SOS1 has been reported as a confirmed de novo occurrence in at least 2 patients with clinical features of a RASopathy (PS2_VeryStrong; PMID 17143282). This variant has also been identified in at least 7 independent occurrences in patients with clinical features of a RASopathy (PS4; PMIDs: 26297936, 25862627, 17143282, 21387466, 19020799, 23885229, 22190897, 19352411). This variant was absent from large population studies (PM2; gnomAD, http://gnomad.broadinstitute.org). In vitro functional studies provide some evidence that the p.Arg552Ser variant may impact protein function (PS3; PMID: 27304678). This residue has been identified as a hot spot. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been upgraded with expert judgement (PM1_Strong). Computational prediction tools and conservation analysis suggest that the p.Arg552Ser variant may impact the protein (PP3). The variant is located in the SOS1 gene, which has been defined by the ClinGen RASopathy Expert Panel as a gene with a low rate of benign missense variants and pathogenic missense variants are common (PP2; PMID: 29493581). In summary, this variant meets criteria to be classified as pathogenic for RASopathies in an autosomal dominant manner. Rasopathy-specific ACMG/AMP criteria applied (PMID:29493581): PS2_VeryStrong, PS4, PM2, PS3, PM1_Strong, PP2, PP3.
Met criteria codes
PS2_Very Strong
The p.Arg552Ser variant was identified in 2 de novo occurrences in patients with Noonan syndrome. Variants were absent from both parents and paternity was confirmed for each.

PS3
variant increased p-ERK signaling (PMID 27304678)

PS4
This variant was reported in at least 7 patients with clinical features of NS (PMID: 26297936, 25862627, 17143282, 21387466, 19020799, 23885229, 22190897, 19352411)

PP2
SOS1 gene meets PP2
PP3
REVEL score 0.863
PM2
Variant is absent from gnomAD
PM1_Strong
This residue has been identified as a hot spot. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been upgraded with expert judgement.
Not Met criteria codes
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BS4
BS2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP5
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP7
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP2
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BP3
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PS1
This variant will be used to support the pathogenicity of the c.1656G>T transition in SOS1
PP1
Variant segregated in one mother child duo (PMID: 23885229).

PM4
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
PM5
There are multiple pathogenic variants at this codon. These variants would have received PM5_Strong but the RAS EP decided that PM1 and PM5 cannot be used simultaneously and therefore this rule has been removed
PM6
PM6 cannot be applied because PS2_VS has been applied.

Approved on: 2019-05-10
Published on: 2019-06-28
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.